Company news

Cogent Biosciences, Inc. news in 2023

Cogent Biosciences, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Cogent Biosciences Announces Positive Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

December 10, 2023

Cogent Biosciences Announces Positive Initial Data from Phase 2 SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)

December 8, 2023

Cogent Biosciences Presents New Preclinical Data Highlighting Potential Best-in-Class Potency and Selectivity of ErbB2 and PI3Kα inhibitor programs at the San Antonio Breast Cancer Symposium

December 6, 2023

Cogent Biosciences to Host Investor Webcast on December 11, 2023 at 8: 00 AM ET to Review Clinical Data Being Presented at American Society of Hematology (ASH) Annual Meeting

December 3, 2023

Cogent Biosciences Announces Poster Presentations at Upcoming San Antonio Breast Cancer Symposium

November 28, 2023

Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2023 Financial Results

November 1, 2023

Cogent Biosciences Presents Preclinical Data Highlighting Precision Oncology Pipeline at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October 13, 2023

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2023 Financial Results

August 7, 2023

Cogent Biosciences Announces Closing of Upsized Public Offering of Common Stock

June 8, 2023

Cogent Biosciences Announces Participation in the Jefferies Healthcare Conference

June 6, 2023

Cogent Biosciences Announces Proposed Public Offering of Common Stock

June 5, 2023

Cogent Biosciences Announces Positive Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST)

June 2, 2023

Cogent Biosciences to Host Investor Webcast to Discuss Lead-In Data Being Presented at ASCO from the Ongoing Phase 3 PEAK Trial in Patients with Gastrointestinal Stromal Tumors (GIST)

May 22, 2023

Cogent Biosciences Reports Recent Business Highlights and First Quarter 2023 Financial Results

May 8, 2023

Cogent Biosciences Presents Preclinical Data at AACR Annual Meeting Highlighting Precision Therapy Pipeline and Announces Initiation of Part 2 of the Registration-Enabling APEX Trial with Bezuclastinib in Advanced Systemic Mastocytosis

April 16, 2023

Cogent Biosciences Announces Participation at Upcoming Investor Conferences

April 11, 2023

Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results

March 13, 2023

Cogent Biosciences Announces Planned 2023 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Cancer Therapeutics

January 8, 2023

Cogent Biosciences Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference

January 4, 2023

Decks in 2023